Contemporary advances in therapeutic portfolio of 2-Azetidinones

b-lactam derivatives

Authors

  • Kaur Rajneesh Maharishi Markandeshwar (Deemed to be University)
  • Raman Singh Maharishi Markandeshwar (Deemed to be University)
  • Priyanka Ahlawat Maharishi Markandeshwar (Deemed to be University)
  • Parul Kaushik Maharishi Markandeshwar (Deemed to be University)
  • Kuldeep Singh Maharishi Markandeshwar University

Abstract

The heterocycle moieties form the site of reaction in many enzymes and co-enzymes and also act as an important pharmacophore in the pharmaceutical drug designs. 2-Azetidinones are the 2-carbonyl derivatives of azetidine, more commonly known as ?-lactams. These structural entities occupied a central role in the vigil against bacterial infections over the past few decades. A subclass of these heterocyclic systems, monobactams or monocyclic ?-lactam derivatives exhibits several biological activities including antibacterial, antifungal, antiprotozoal, anti-mycobacterial, anti-HIV, antiviral, antimalarial, antioxidant, apoptotic inhibitors, anti-inflammatory activity, anticancer activity, herbicidal activity, etc. Monobactams has resistant to the ?-lactamase enzyme and could be a reasonable starting point for developing new drugs or inhibitors. In the present review, pharmacological activities of monocyclic ?-lactam derivatives have been discussed with respect to current research in the structure-activity relationships in different therapeutic areas.

Downloads

Download data is not yet available.

Published

2020-01-06

Issue

Section

Review Articles

How to Cite

Contemporary advances in therapeutic portfolio of 2-Azetidinones. (2020). Chemical Biology Letters, 7(1), 13-26. https://pubs.thesciencein.org/journal/index.php/cbl/article/view/152

Most read articles by the same author(s)